Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
morifecidine mesylate
- Development stage
- Unknown
- Lead developer
- HEC Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Morifecidine mesylate (HEC72702) is an orally bioavailable small molecule Hepatitis B virus (HBV) capsid assembly modulator (CAM) being developed by HEC Pharm (Dongguan Chang'an Dongyangguang New Drug Research and Development). It belongs to the class of core protein allosteric modulators (CpAMs) that target the HBV core protein (HBcAg). By binding to the core protein, morifecidine interferes with the proper assembly of the viral capsid, leading to the formation of aberrant, non-functional capsids or preventing the encapsidation of pregenomic RNA (pgRNA). This mechanism effectively inhibits viral replication and reduces the production of new virions. In clinical trials, morifecidine mesylate has been evaluated in combination with ritonavir, which serves as a pharmacokinetic enhancer to increase systemic exposure of the drug.
- Other names
- morifecidine
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on morifecidine mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on morifecidine mesylate.